12,372 trials
Depressive Disorder, Major
Primary: Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8) — -14.5; -15.4 Scores on a scale…
Choroidal Neovascularization Secondary to Pathologic Myopia
Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001
Complicated Intra-abdominal Infections · Complicated Appendicitis
Primary: Number of Participants With a Favorable Clinical Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 177; 187; 7; 7…
Status Epilepticus
Primary: Percentage of Participants Who Achieved Seizure Free Interval of At Least 30 Minutes After Initial Dose (Dose 1) of Study Drug — 48.0 percentage of participants
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
Amyotrophic Lateral Sclerosis
Primary: Overall Survival Rate at 18 Months — 67.5; 69.4 percentage of partcipants — p=0.71
Chronic Hepatitis C Virus · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Non-inferiority of Arm A to Arm B — 97.8; 93.5 percentage of participants
Bariatric Surgery Candidate
Primary: 0-1 h Postoperative Pain Level — 3.9762; 4.3149 units on a scale
Diabetes Mellitus, Type 2
Primary: Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline) — -0.93; 0.21 Percentage (%) — p=<0.0001
Fabry Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 163; 74; 7 Participants
Visceral Leishmaniosis · HIV-infection/Aids
Primary: Probability of Relapse-free Survival — 79; 71 percentage probability
Psoriasis
Primary: Part I: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 — 81.7; 13.6 Percentage of Participants — p=<0.0001
Chronic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) — 399; 748 Participants
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels — 0.536; 0.494 proportion of participants